The latest price target for Cabaletta Bio (NASDAQ:CABA) was reported by Wells Fargo on August 12, 2024. The analyst firm set a price target for $20.00 expecting CABA to rise to within 12 months (a possible 227.33% upside). 24 analyst firms have reported ratings in the last year.

The latest analyst rating for Cabaletta Bio (NASDAQ:CABA) was provided by Wells Fargo, and Cabaletta Bio maintained their overweight rating.

The last upgrade for Cabaletta Bio Inc happened on January 27, 2023 when Morgan Stanley raised their price target to $16. Morgan Stanley previously had an equal-weight for Cabaletta Bio Inc.

The last downgrade for Cabaletta Bio Inc happened on August 30, 2022 when Morgan Stanley changed their price target from $15 to $3 for Cabaletta Bio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cabaletta Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cabaletta Bio was filed on August 12, 2024 so you should expect the next rating to be made available sometime around August 12, 2025.

While ratings are subjective and will change, the latest Cabaletta Bio (CABA) rating was a maintained with a price target of $35.00 to $20.00. The current price Cabaletta Bio (CABA) is trading at is $6.11, which is out of the analyst’s predicted range.